Advertisements


We are Sorry, This Page doesn't Exist


Benzinga"s Daily Biotech Pulse: Sarepta"s DMD Gene Therapy, Anika"s Flunked Trial, Eidos To Commence Trading

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 19) read more.....»»

Category: blogSource: benzinga45 min. ago

Sarepta shares rocket 40% on promising early results for DMD gene therapy

Earlier this year, Sarepta’s CEO bet the company would be known best for its genetic medicine advances. The latest results suggest he could be right......»»

Category: topSource: marketwatch2 hr. 30 min. ago

Sarepta Obtains Impressive Early Data From DMD Gene Therapy Study

Sarepta Obtains Impressive Early Data From DMD Gene Therapy Study.....»»

Category: topSource: seekingalpha4 hr. 0 min. ago

Sarepta Shares Up 37% on Gene Therapy Results

Good news about an early-stage clinical trial has raised hopes that the treatment could save children’s lives......»»

Category: topSource: barrons5 hr. 45 min. ago

Sarepta Gets Boost From Early Trial Results on Muscular Dystrophy Treatment

Sarepta Therapeutics Inc. gained about $2.5 billion of stock market value after an early stage trial of a gene therapy showed promise in its ability to treat patients with Duchenne muscular dystrophy......»»

Category: smallbizSource: wsj10 hr. 45 min. ago

Brainstorm Health: Sarepta Duchenne Therapy, CVS Drug Delivery, Trump’s New Obamacare Move

Brainstorm Health Daily: June 19, 2018 Hello, readers--This is Sy. Shares of biotech Sarepta Therapeutics shot off to the moon Tuesday after the company announced early data on its experimental gene therapy to treat .....»»

Category: europeSource: fortune16 hr. 30 min. ago

Analyst: Sarepta"s DMD Gene Therapy Results "Dramatic And Far Exceeding Expectations"

Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported some encouragi.....»»

Category: blogSource: benzinga19 hr. 0 min. ago

Sarepta shares rocket 50% on promising early results for DMD gene therapy

Earlier this year, Sarepta’s CEO bet the company would be known best for its genetic medicine advances. The latest results suggest he could be right......»»

Category: topSource: marketwatch20 hr. 45 min. ago

Sarepta shares skyrocket 66% on early positive results for DMD gene therapy

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatch21 hr. 0 min. ago

Sarepta Hits Record High As Duchenne Muscular Dystrophy Gene Therapy Yields Positive Results In Early-Stage Study

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares, halted shortly before Tuesday's open, opened higher by more than 50 percent. read more.....»»

Category: blogSource: benzinga21 hr. 15 min. ago

Baird analyst calls Sarepta gene therapy data a "game changer"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall22 hr. 30 min. ago

Sarepta jumps 53% to $161.01 after gene therapy data top expectations

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall22 hr. 30 min. ago

Solid Biosciences rallies 17% to $34.44 following Sarepta gene therapy data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall22 hr. 30 min. ago

Sarepta: DMD gene therapy shows 38.2% of micro-dystrophin in Phase 1/2a study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall22 hr. 30 min. ago

Sarepta DMD gene therapy shows 38% of micro-dystrophin in Phase 1/2a study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall22 hr. 30 min. ago

Sarepta gene therapy produced "jaw-dropping" protein increases, STAT says

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall22 hr. 30 min. ago

Sarepta shares rocket 55% on positive early results for DMD gene therapy

Sarepta Therapeutics Inc. shares rocketed 55.6% in extremely heavy Tuesday morning trade after the company reported positive early results from a phase 1/2a gene therapy clinical trial for three patients with the rare.....»»

Category: topSource: marketwatch22 hr. 30 min. ago

Nationwide Children"s gene therapy inventors hired away by pharma giants – why that"s good for recruitment

Two lead inventors of three of the four gene therapy treatments that Nationwide Children's Hospital has licensed to spinoffs have been hired away since fall and work full-time at big pharmaceutical companies. Children's counts those as wins......»»

Category: topSource: bizjournalsJun 19th, 2018

Gene-Editing Selloff Is Overdone

The science-journal studies that ignited a rout in Crispr Therapeutics, Editas Medicine, and other gene-therapy shares look to have been misunderstood......»»

Category: topSource: barronsJun 16th, 2018

FDA Anesthesiology & Respiratory Therapy Devices Panel to hold a meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 14th, 2018